Deep Apple Therapeutics CEO Spiros Liras (L) and interim CSO Paul Da Silva Jardine

For­mer ex­ecs from Pfiz­er obe­si­ty drug pro­gram have start­ed a new biotech with $52M from VC fund ATP

Two for­mer chem­istry VPs who worked at Pfiz­er’s car­dio­vas­cu­lar and meta­bol­ic re­search group have come to­geth­er to build a new biotech as the obe­si­ty drug de­vel­op­ment field soars.

The start­up, called Deep Ap­ple Ther­a­peu­tics, has a lead pro­gram that goes af­ter an undis­closed in­flam­ma­to­ry skin dis­ease and will en­ter the clin­ic around 2025, but its lot­tery tick­et is an oral small mol­e­cule triple G (GLP-1/GIP/glucagon) for obe­si­ty and oth­er non-GLP-1 pro­grams for meta­bol­ic dis­or­ders.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.